San Diego, September 19, 2013 – Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company announced today that Ms. Lisa Miller has been appointed to the position of Chief Executive Officer.
With more than 25 years of experience in the global diagnostic and devices industries, Ms. Miller most recently served as Corporate Vice President at DAKO, an Agilent Technologies Company, headquartered in Copenhagen, Denmark. She was responsible for global operations of their cancer diagnostics business, with $375M in revenue and over 500 employees worldwide. She was also a member of the Board of Directors and Corporate Management Team. Under her leadership, Ms. Miller redefined DAKO’s strategy and restructured the commercial operations of the company, resulting in its 2012 acquisition by Agilent Technologies.
Prior to joining DAKO, Ms. Miller was with Invitrogen Corporation, in the position of Vice President, Commercial Business and head of the Americas region. Prior to this, she held several positions of increasing commercial responsibility at Thermo Fisher Scientific, most recently as Vice President Sales with accountability for a $600M business. During her tenure at Thermo Fisher, Ms Miller held several senior sales and account management positions focused on growth and business development through contractual relationships with major pharmaceutical companies.
Ms. Miller commented: “I am very enthusiastic about joining Prometheus to drive our diagnostic strategy across the chosen therapeutic platforms. I believe Prometheus plays a key role in Nestlé Health Science’s ambition to create a new segment in health care, using diagnostic and nutrition science solutions in the management of disease.”
“We are delighted to have Ms. Miller join our team,” commented Cathy Kerzner, interim CEO of Prometheus. “We anticipate she will make a tremendous contribution to our growth strategy, with her depth in diagnostics along with her proven record of performance.’
Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with more targeted solutions to optimize care for their patients. Prometheus became part of Nestlé Health Science in July 2011. The corporate offices of Prometheus are located in San Diego, California. For more information about Prometheus, please visit www.prometheuslabs.com.
About Nestlé Health Science
Nestlé Health Science, a wholly-owned subsidiary of Nestlé, intends to spearhead the development of science-based personalised nutritional solutions. Building on its core HealthCare Nutrition business, the company has ambitions to address chronic conditions in the area of Gastrointestinal Health, Metabolic Health and Brain Health. Nestlé Health Science offers nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages. Nestlé Health Science employs around 3,000 people worldwide and has its headquarters in Vevey, Switzerland.